Comment: In the process of preparing for an FDA
clinical trial, undisclosed when FDA approval might
occur (my guess would be sometime in 2022). They
state "A proof-of-concept study found the company's
radio frequency technology was able to continuously
measure glucose levels with at least 90% accuracy, ...
... compared to the estimated 70% rate for traditional
continuous glucose monitors." To the best of my know-
ledge, leading CGMs are at least 90% accurate, so I
suspect that 70% figure is a misstatement.